TRANSAVE is a biotechnology company whose mission
is to improve the treatment of serious lung diseases through the company's next generation, proprietary liposomal delivery technology providing prolonged release of a drug in the lung while minimizing systemic exposure.

Transave is currently developing new therapies which may improve the therapeutic index for treating lung infections that have a pseudomonas component, such as cystic fibrosis and bronchiectasis, and enable non-toxic pulmonary delivery of siRNA molecules. All of our therapies are delivered via inhalation directly to the site of the disease.

Patients CLICK HERE  Physicians CLICK HERE

Thursday, October 23, 2008 
Company Presentation
22nd Annual North American Cystic Fibrosis Conference
Orlando, FL

Wednesday, September 10, 2008 (3:15 PM)
Company Presentation
BioPharm America 2008
Atlanta, GA